Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT06468956

Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR-1819 Injection in Patients With Moderate to Severe Atopic Dermatitis

Status
Active Not Recruiting
Phase
Phase 3
Study type
Interventional
Enrollment
652 (actual)
Sponsor
Guangdong Hengrui Pharmaceutical Co., Ltd · Industry
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with atopic dermatitis.

Conditions

Interventions

TypeNameDescription
DRUGSHR-1819SHR-1819 injection
DRUGPlaceboplacebo

Timeline

Start date
2024-06-14
Primary completion
2026-03-31
Completion
2026-03-31
First posted
2024-06-21
Last updated
2025-09-11

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06468956. Inclusion in this directory is not an endorsement.

Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis (NCT06468956) · Clinical Trials Directory